The news came July 21 during the insurer’s second-quarter earnings call.
Anthem joins UnitedHealth in waiting to cover the drug since its FDA approval, while a handful of Blue Cross Blue Shield affiliates have declined to cover it.
Anthem awaiting more Aduhelm data before deciding coverage
Anthem will further evaluate Aduhelm before it announces whether or not the Alzheimer’s drug will be covered, Yahoo News reported.
